@article{ref1,
title="Ketamine for acute suicidality in the emergency department: A systematic review",
journal="American journal of emergency medicine",
year="2021",
author="Maguire, Lindsay and Bullard, Timothy and Papa, Linda",
volume="43",
number="",
pages="54-58",
abstract="INTRODUCTION: There are no emergent pharmaceutical interventions for acute suicidal ideation, a common presenting complaint in the ED. Ketamine is a NMDA agonist frequently used by ED physicians for sedation and analgesia. Prior evidence from studies conducted in inpatient psychiatry units suggests that ketamine may have a role in alleviating treatment-resistant depression as well as suicidal ideation. METHODS: PubMed, MEDLINE, and Cochrane reviews were queried for articles related to keywords ketamine, suicidality, suicidal ideation, and emergency department/room. Relevant articles were selected and reviewed by two separate authors. RESULTS: Three relevant, prospective studies were identified with a mean sample size of 25.7. Each was performed using 0.2 mg/kg ketamine for individuals receiving active treatment. Each study reported a decrease in depressive symptoms among those receiving ketamine. One study reported a significant reduction in SI when compared to placebo at 90 min that became non-significant by 230 min. No significant adverse events were reported in any study. CONCLUSION: Current evidence suggests that ketamine is a promising, safe potential intervention for acute suicidality in the ED. Convincing evidence for efficacy of ketamine for acute suicidal ideation remains lacking, and this promising potential intervention should be further investigated.<p /><p>Language: en</p>",
language="en",
issn="0735-6757",
doi="10.1016/j.ajem.2020.12.088",
url="http://dx.doi.org/10.1016/j.ajem.2020.12.088"
}